A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-11. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
== Biosynthesis == Patellamide A originates from a ribosomal peptide, making it a member of the RiPP superfamily of natural products. This was determined after genome sequencing of P. didemi showed a lack of non ribosomal peptide synthetases. The biosynthetic gene cluster for patellamide A contains the genes patA, patB, patC, patD, patE, patF and patG. These genes, when introduced into E. coli, cause the production of patellamide A, definitively confirming their responsibility for patellamide A biosynthesis. The gene patE encodes the precursor peptide that contains the primary sequences of patellamides A and C. It has been proposed by Schmidt et al. that this prepatellamide is heterocyclized to form the oxazoline and thiazoline rings by PatD2. It is proposed that PatG1 is subsequently involved in oxidizing the thiazoline rings to the thiazole rings found in patellamide A. The peptide is then cleaved, possibly by PatA or PatG2, and cyclized, the cyclization is likely aided by adenylation by PatD1, forming the two cyclic peptides, patellamides A and C. Although all the amino acids used in the production of patellamide A are L-amino acids, some of the amino acids found in natural patellamide A are the D-epimers. It is proposed that epimerization of these amino acids occurs spontaneously. This was determined by comparison to a similar system, lissoclinamide 7.
The food industry is a major consumer of amino acids, especially glutamic acid, which is used as a flavor enhancer, and aspartame (aspartylphenylalanine 1-methyl ester), which is used as an artificial sweetener. Amino acids are sometimes added to food by manufacturers to alleviate symptoms of mineral deficiencies, such as anemia, by improving mineral absorption and reducing negative side effects from inorganic mineral supplementation. Amino acids are low-cost feedstocks used in chiral pool synthesis as enantiomerically pure building blocks. Amino acids are used in the synthesis of some cosmetics. The chelating ability of amino acids is sometimes used in fertilizers to facilitate the delivery of minerals to plants in order to correct mineral deficiencies, such as iron chlorosis. These fertilizers are also used to prevent deficiencies from occurring and to improve the overall health of the plants.
=== Physical === Lawrencium is the last actinide. Authors considering the subject generally consider it a group 3 element, along with scandium, yttrium, and lutetium, as its filled f-shell is expected to make it resemble the other 7th-period transition metals. In the periodic table, it is to the right of the actinide nobelium, to the left of the 6d transition metal rutherfordium, and under the lanthanide lutetium with which it shares many physical and chemical properties. Lawrencium is expected to be a solid under normal conditions and have a hexagonal close-packed crystal structure (c/a = 1.58), similar to its lighter congener lutetium, though this is not yet known experimentally. The enthalpy of sublimation of lawrencium is estimated at 352 kJ/mol, close to the value of lutetium and strongly suggesting that metallic lawrencium is trivalent with three electrons delocalized, a prediction also supported by a systematic extrapolation of the values of heat of vaporization, bulk modulus, and atomic volume of neighboring elements to lawrencium. This makes it unlike the immediately preceding late actinides which are either known to be (fermium and mendelevium) or expected to be (nobelium) divalent. The estimated enthalpies of vaporization show that lawrencium deviates from the trend of the late actinides and instead matches the trend of the succeeding 6d elements rutherfordium and dubnium, consistent with lawrencium's interpretation as a group 3 element.
This is further reinforced by a 2020 Cochrane systematic review which did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to sulfonylureas. This same review also did not find improvement in health-related quality of life. In individuals with impaired-glucose tolerance, a 2019 systematic review only found one suitable trial comparing the effects of Sulphonylurea with metformin in reduction or delay of risk of developing type 2 diabetes, however this trial did not report patient-relevant outcomes. Another systematic review completed in the same year suggested that there is limited evidence if the combined use of Metformin with Sulphonylurea compared to the combination of Metformin plus another glucose-lowering intervention, provides benefit or harm in mortality, severe adverse events, macrovascular and microvascular complications. Combined Metformin and Sulphonylurea therapy did appear to lead to higher risk of Hypoglycemia.
In morphology, analogous traits arise when different species live in similar ways and/or a similar environment, and so face the same environmental factors. When occupying similar ecological niches (that is, a distinctive way of life) similar problems can lead to similar solutions. The British anatomist Richard Owen was the first to identify the fundamental difference between analogies and homologies. In biochemistry, physical and chemical constraints on mechanisms have caused some active site arrangements such as the catalytic triad to evolve independently in separate enzyme superfamilies. In his 1989 book Wonderful Life, Stephen Jay Gould argued that if one could "rewind the tape of life [and] the same conditions were encountered again, evolution could take a very different course." Simon Conway Morris disputes this conclusion, arguing that convergence is a dominant force in evolution, and given that the same environmental and physical constraints are at work, life will inevitably evolve toward an "optimum" body plan, and at some point, evolution is bound to stumble upon intelligence, a trait presently identified with at least primates, corvids, and cetaceans.
Sources: en.wikipedia.org
Black and Hispanic women are at higher risk for isoniazid-induced hepatotoxicity. When it happens, isoniazid-induced liver toxicity has been shown to occur in 50% of patients within the first 2 months of therapy. Some recommend that liver function should be monitored carefully in all people receiving it, but others recommend monitoring only in certain populations. Headache, poor concentration, weight gain, poor memory, insomnia, and depression have all been associated with isoniazid use. All patients and healthcare workers should be aware of these serious side effects, especially if suicidal ideation or behavior are suspected.
He recommended that the diets of the pregnant and nursing females and the weaned cubs be switched from lean horse meat to goat – including calcium- and phosphorus-containing bones – and cod liver oil, solving the problem. Subsequently, researchers realized that animal models such as dogs and rats could be used for rickets research, leading to the identification and naming of the responsible vitamin in 1922. In 1914, American researchers Elmer McCollum and Marguerite Davis had discovered a substance in cod liver oil which later was named "vitamin A". Edward Mellanby, a British researcher, observed that dogs that were fed cod liver oil did not develop rickets, and (wrongly) concluded that vitamin A could prevent the disease. In 1922, McCollum tested modified cod liver oil in which the vitamin A had been destroyed. The modified oil cured the sick dogs, so McCollum concluded the factor in cod liver oil which cured rickets was distinct from vitamin A. He called it vitamin D because it was the fourth vitamin to be named. In 1925, it was established that when 7-dehydrocholesterol is irradiated with light, a form of a fat-soluble substance is produced, now known as vitamin D3. Adolf Windaus, at the University of Göttingen in Germany, received the Nobel Prize in Chemistry in 1928 "for the services rendered through his research into the constitution of the sterols and their connection with the vitamins".
In May 2009, Gil Kerlikowske, Director of the ONDCP – Obama's drug czar – indicated that the Obama administration did not plan to significantly alter drug enforcement policy, but that it would not use the term "war on drugs", considering it to be "counter-productive". In August 2010, Obama signed the Fair Sentencing Act into law, reducing the 100:1 sentencing disparity between crack and powder cocaine to 18:1 for pending and future cases. In 2013, Obama's Justice Department issued a policy memorandum known as the Cole Memo, stating that it would defer to state laws that authorize the production, distribution and possession of cannabis, "based on assurances that those states will impose an appropriately strict regulatory system." In 2011, the Global Commission on Drug Policy, an international non-governmental group composed primarily of former heads of state and government, and leaders from various sectors, released a report that stated, "The global war on drugs has failed." It recommended a paradigm shift, to a public health focus, with decriminalization for possession and personal use. Obama's ONDCP did not support the report, stating: "Drug addiction is a disease that can be successfully prevented and treated. Making drugs more available ... will make it harder to keep our communities healthy and safe."
Over longer periods, or populations at high risk of obesity, GLP-1 receptor agonists may have a more favorable cost-effectiveness analysis. Despite the economic considerations, GLP-1 receptor agonists are included in clinical guidelines for obesity management due to their demonstrated efficacy in weight loss and cardiometabolic risk improvement. The high cost has been identified and is seen as a barrier to access and widespread use in many healthcare systems.
Sources: en.wikipedia.org
== Adverse effects == Common side effects include pneumonia and urinary tract infections. Severe side effects may include blood clots or cardiac arrest. Andexanet alfa has a boxed warning that it is associated with arterial and venous blood clots, ischemic events, cardiac arrest, and sudden deaths.
=== Regulation by insulin in animals === In animals, regulation of blood glucose levels by the pancreas in conjunction with the liver is a vital part of homeostasis. The beta cells in the pancreatic islets are sensitive to the blood glucose concentration. A rise in the blood glucose concentration causes them to release insulin into the blood, which has an effect particularly on the liver, but also on fat and muscle cells, causing these tissues to remove glucose from the blood. When the blood sugar falls the pancreatic beta cells cease insulin production, but, instead, stimulate the neighboring pancreatic alpha cells to release glucagon into the blood. This, in turn, causes the liver to release glucose into the blood by breaking down stored glycogen, and by means of gluconeogenesis. If the fall in the blood glucose level is particularly rapid or severe, other glucose sensors cause the release of epinephrine from the adrenal glands into the blood. This has the same action as glucagon on glucose metabolism, but its effect is more pronounced. In the liver glucagon and epinephrine cause the phosphorylation of the key, regulated enzymes of glycolysis, fatty acid synthesis, cholesterol synthesis, gluconeogenesis, and glycogenolysis. Insulin has the opposite effect on these enzymes. The phosphorylation and dephosphorylation of these enzymes (ultimately in response to the glucose level in the blood) is the dominant manner by which these pathways are controlled in the liver, fat, and muscle cells.
=== Proposed long-range version === On June 26, 1972, a long-range version of the Il-86, the Il-86D (for Russian: "дальний"; transliterated: "dal’niy"; meaning "long-range"), was ordered into development by the Soviet cabinet. Design was completed in June 1976. The Il-86D would have had a marginally extended wing span, carried additional fuel, and had a range of some 8,500 km (4,600 nmi). Later announcements stated that a version of the Il-86D with Lotarev D-18 engines had entered development in March 1975. This version would have had a 147,500 kg (325,000 lb) empty weight, a 300,000 kg/660,000 lb maximum take-off weight, a fuel capacity of some 150,000 kg (330,000 lb), a wing area of 325 m2 (5,300 ft2), and a range of 10,200 km (5,500 nmi). It evolved into the Il-96.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.